Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indacaterol + glycopyrronium is a fixed-dose combination inhaled medication used as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Indacaterol is an ultra-long-acting beta-2 adrenergic agonist (LABA) that relaxes bronchial smooth muscle to improve airflow. Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that blocks the action of acetylcholine on airway smooth muscle cells, leading to bronchodilation. The combination provides rapid onset of action within 5 minutes and sustained bronchodilation over 24 hours. It is not indicated for asthma or acute relief of symptoms[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indacaterol + glycopyrronium.